Chemotherapy in ovarian carcinoma: intravenous or intraperitoneal?

Although the majority of women with advanced ovarian carcinoma respond to cisplatin-based intravenous chemotherapy, long-term survival is experienced by less than 30 per cent of treated patients. Efforts to improve the efficacy of treatment have focused on dose intensification and direct drug delivery into the peritoneal cavity.